NCT06132165 2025-11-21
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
Clinical Trials
12 trialsNCT04730583 2025-02-21
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT06120036 2025-02-21
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT02700230 2024-09-27
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Mayo Clinic
Phase 1 Completed
NCT05438290 2024-05-06
DPCP to Treat Cutaneous Neurofibromas Associated With NF1
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02415153 2022-04-25
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00727233 2019-12-12
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03649165 2018-11-08
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
AstraZeneca
Phase 1 Completed
NCT00865644 2017-01-10
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Massachusetts General Hospital
Phase 1 Completed
NCT00352599 2016-11-22
NF1
University of California, Los Angeles
Phase 1 Completed
NCT00053937 2015-04-30
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00352495 2014-02-13
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Children's Oncology Group
Phase 1 Completed